XNAS · Healthcare · Biotechnology
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q4 2025 | — | -1.50 | — | $20,020 | — | +7.29% | +0.72% | -4.45% |
| 2025-12-04 | Q3 2025 | — | -1.50 | — | $62,500 | — | — | — | — |
| 2025-09-30 | Q2 2025 |
| — |
| -2.90 |
| — |
| — |
| — |
| — |
| — |
| — |
| 2025-04-25 | Q4 2024 | — | -1.37 | — | $1,719 | — | -1.96% | -1.10% | -7.23% |
| 2024-11-22 | Q3 2024 | — | -2.77 | — | $68,161 | — | +5.58% | +15.67% | +1.33% |
| 2024-09-30 | Q2 2024 | — | 10.61 | — | $127,151 | — | -5.53% | -4.45% | +9.72% |
| 2024-06-06 | Q1 2024 | — | -1.37 | — | $268,835 | — | -2.17% | -5.98% | -8.70% |
| 2024-04-18 | Q4 2023 | — | -4.06 | — | $173,059 | — | -4.34% | -26.48% | -58.01% |
Showing last 8 quarters.